Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium

被引:21
作者
Mourits, MJE
Hollema, H
De Vries, EGE
Ten Hoor, KA
Willemse, PHB
Van der Zee, AGJ
机构
[1] Univ Groningen Hosp, Dept Obstet & Gynecol, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Pathol, NL-9713 GZ Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands
关键词
tamoxifen; apoptosis; M30; caspase; Fas; Fas ligand; Bcl-2; endometrium;
D O I
10.1053/hupa.2002.32226
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tamoxifen increases endometrial cell proliferation and the incidence of endometrial cancer in postmenopausal women. The purpose of this study was to evaluate apoptosis and apoptosis-related factors in endometrium. in relation to tamoxifen exposure. We analyzed benign postmenopausal endometrium. from breast cancer patients receiving tamoxifen (n = 35) and from controls (n = 24), and endometrial cancer tissue from tamoxifen-treated breast cancer patients (n = 15) and endometrial cancer from women without tamoxifen exposure (n = 51). Apoptosis was examined morphologically, and the percentage of apoptotic epithelial cells was defined as the apoptotic index. In the benign samples, the presence of apoptotic cells was also evaluated immunohistochemically by the expression of caspase-3 and the monoclonal antibody M30. The expression of Fas, FasL, and Bcl-2 was analyzed in all tissue samples. No differences were observed in the mean apoptotic index in benign endometrium. in tamoxifen users (0.17%) versus controls (0.08%), or in tamoxifen-exposed (2.46%) versus nonexposed endometrial cancer (2.28%). However, the ratio of the apoptotic index with the previously reported proliferation index was lower in benign endometrium. from tamoxifen users than in controls (0.02 +/- 0.026 vs. 0.05 +/- 0.03, Mann-Whitney U <0.005). In benign endometrium. FasL was more frequently expressed in tamoxifen-users than in controls (chi(2) <0.05). We conclude that the apoptosis/proliferation ratio in benign endometrium. from tamoxifen users is lower than in controls, indicating that the tamoxifen-induced higher proliferation is not compensated for by increased apoptosis. An imbalance between cell proliferation and apoptosis, and possibly suppression of the antitumor immune response by FasL overexpression in tamoxifen-exposed endometrium might play a role in the development of endometrial cancer in tamoxifen users. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 36 条
[1]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[2]  
Carr NJ, 2000, ARCH PATHOL LAB MED, V124, P1768
[3]   Second cancers after adjuvant tamoxifen therapy for breast cancer [J].
Curtis, RE ;
Boice, JD ;
Shriner, DA ;
Hankey, BF ;
Fraumeni, JF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (12) :832-834
[4]   Effect of tamoxifen on endometrial proliferation [J].
Decensi, A ;
Fontana, V ;
Bruno, S ;
Gustavino, C ;
Gatteschi, B ;
Costa, A .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :434-440
[5]   The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells [J].
Diel, P ;
Smolnikar, K ;
Michna, H .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 58 (02) :87-97
[6]  
Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO
[7]  
2-7
[8]   ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14 [J].
FISHER, B ;
COSTANTINO, JP ;
REDMOND, CK ;
FISHER, ER ;
WICKERHAM, DL ;
CRONIN, WM ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
EVANS, J ;
FARRAR, W ;
KAVANAH, M ;
LICKLEY, HL ;
MARGOLESE, R ;
PATERSON, AHG ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :527-537
[9]  
FOMANDER T, 1989, LANCET, V1, P117
[10]  
Gratas C, 1998, CANCER RES, V58, P2057